DNA–protein interactions (such as those found in Myc–Max inhibitors) and protein degradation (such as that caused by EZH2 inhibitors) have been proposed as novel therapeutic means to target critical components in cancer survival pathways [5,6,9]. The gene discussed is EZH2; the disease is cancer.